(Q37886036)

24 August 2017

1 reference

title

New therapeutic options for metastatic malignant insulinomas (English)

1 reference

24 August 2017

1

Wouter W de Herder

1 reference

24 August 2017

Ellen van Schaik

2

1 reference

24 August 2017

Dik Kwekkeboom

series ordinal

3

1 reference

24 August 2017

Richard A Feelders

series ordinal

4

1 reference

24 August 2017

publication date

1 September 2011

1 reference

24 August 2017

published in

Clinical Endocrinology

1 reference

24 August 2017

volume

75

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

277-284

1 reference

Well-differentiated pancreatic tumor/carcinoma: insulinoma

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Pancreatic Endocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Surgical management of patients with insulinomas: Result of 292 cases in a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Diazoxide treatment for insulinoma: a national UK survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Drug-induced hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Management of Intractable Hypoglycemia With Yttirum-90 Radioembolization in a Patient With Malignant Insulinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Malignant metastatic insulinoma-postoperative treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Individual patient data analysis to assess modifications to the RECIST criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

The potential role of mTOR inhibitors in the treatment of endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Glycemic control in patients with insulinoma treated with everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04145.X

10.1111/J.1365-2265.2011.04145.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference